-+ 0.00%
-+ 0.00%
-+ 0.00%

REPLIMUNE SHARES DOWN 25% PREMARKET AFTER FDA STAFF FLAGS EFFICACY CONCERNS ON CO'S SKIN CANCER THERAPY

路透·07/28/2026 11:40:13

登錄查看新聞詳情